GNLX Projected Dividend Yield
Genelux Corp ( NASDAQ : GNLX )Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Co.'s primary product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus, a DNA virus. 20 YEAR PERFORMANCE RESULTS |
GNLX Dividend History Detail GNLX Dividend News GNLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |